Lipid- and sugar-modified endomorphins: Novel targets for the treatment of neuropathic pain

Frontiers in Pharmacology

Volumn 4 DEC, Issue , 2013, Pages

  Varamini, Pegah ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Blood brain barrier; Endomorphin; Glycopeptide; Glycosylation; Lipoamino acid; Lipopeptide; Neuropathic pain; Peptide delivery

Indexed keywords

AMINO ACID; CARBOHYDRATE; DELTORPHIN; ENDOMORPHIN 1; ENDORPHIN; FATTY ACID; GLYCOPEPTIDE; LACTOSE; LEUCINE ENKEPHALIN; LIPOAMINO ACID; METENKEPHALIN; MORPHINE; SUBSTANCE P; UNCLASSIFIED DRUG;

ANTINOCICEPTION; BLOOD BRAIN BARRIER; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TRANSPORT; GLYCOSYLATION; HUMAN; LIPIDATION; MEMBRANE PERMEABILITY; NEUROPATHIC PAIN; NONHUMAN; REVIEW; TRANSCYTOSIS;

EID: 84891685294     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00155     Document Type: Review

References (68)

1. Albert, R., Marbach, P., Bauer, W., Briner, U., Fricker, G., Bruns, C., et al. (1993). SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci. 53, 517-525. doi: 10.1016/0024-3205(93)90703-6.
2. Balaz, S. (2000). Lipophilicity in trans-bilayer transport and subcellular pharmacokinetics. Perspect. Drug Discov. 19, 157-177. doi: 10.1023/A:1008775707749.
3. Banks, W. A., Audus, K. L., and Davis, T. P. (1992). Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 13, 1289-1294. doi: 10.1016/0196-9781(92)90037-4.
4. Banks, W. A., and Kastin, A. J. (1985). Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res. Bull. 15, 287-292. doi: 10.1016/0361-9230(85)90153-4.
5. Begley, D. J. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48, 136-146. doi: 10.1111/j.2042-7158.1996.tb07112.x.
6. Bilsky, E. J., Egleton, R. D., Mitchell, S. A., Palian, M. M., Davis, P., Huber, J. D., et al. (2000). Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J. Med. Chem. 43, 2586-2590. doi: 10.1021/jm000077y.
7. Biondi, B., Giannini, E., Negri, L., Melchiorri, P., Lattanzi, R., Rosso, F., et al. (2006). Opioid peptides: synthesis and biological activity of new endomorphin analogues. Int. J. Pept. Res. Ther. 12, 145-151. doi: 10.1007/s10989-006-9015-6.
8. Bock, J. E., Gavenonis, J., and Kritzer, J. A. (2013). Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem. Biol. 8, 488-499. doi: 10.1021/cb300515u.
9. Broadwell, R. D., Balin, B. J., and Salcman, M. (1988). Transcytotic pathway for blood-borne protein through the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 85, 632-636. doi: 10.1073/pnas.85.2.632.
10. Buskas, T., Ingale, S., and Boons, G. J. (2006). Glycopeptides as versatile tools for glycobiology. Glycobiology 16, 113R-136R doi: 10.1093/glycob/cwj125.
11. Chikhale, E. G., Ng, K.-Y., Burton, P. S., and Borchardt, R. T. (1994). Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 11, 412-419. doi: 10.1023/A:1018969222130.
12. Clark, R. J., Jensen, J., Nevin, S. T., Callaghan, B. P., Adams, D. J., and Craik, D. J. (2010). The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. Engl. 49, 6545-6548. doi: 10.1002/anie.201000620.
13. Cravezic, A., Fichna, J., Gach, K., Wyrebska, A., Perlikowska, R., Costentin, J., et al. (2011). Effect of potent endomorphin degradation blockers on analgesic and antidepressant-like responses in mice. Neuropharmacology 61, 1229-1238. doi: 10.1016/j.neuropharm.2011.07.021.
14. Cros, C. D., Toth, I., and Blanchfield, J. T. (2011). Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery. Bioorg. Med. Chem. 19, 1528-1534. doi: 10.1016/j.bmc.2010.12.042.
15. Czapla, M. A., Gozal, D., Alea, O. A., Beckerman, R. C., and Zadina, J. E. (2000). Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am. J. Respir. Crit. Care. Med. 162, 994-999. doi: 10.1164/ajrccm.162.3.9911102.
16. Desino, K. E., Pignatello, R., Guccione, S., Basile, L., Ansar, S., Michaelis, M. L., et al. (2009). TCP-FA4: a derivative of tranylcypromine showing improved blood-brain permeability. Biochem. Pharmacol. 78, 1412-1417. doi: 10.1016/j.bcp.2009.07.027.
17. Dhanasekaran, M., Palian, M. M., Alves, I., Yeomans, L., Keyari, C. M., Davis, P., et al. (2005). Glycopeptides related to β-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. J. Am. Chem. Soc. 127, 5435-5448. doi: 10.1021/ja0432158.
18. Dworkin, R. H., O'Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., et al. (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132, 237-251. doi: 10.1016/j.pain.2007.08.033.
19. Eduardo, P. (1994). 'Carbohydrate handles' as natural resources in drug delivery. Adv. Drug Delivery Rev. 13, 311-323. doi: 10.1016/0169-409X(94)90017-5.
20. Egleton, D. R., Bilsky, J. E., Tollin, G., Dhanasekaran, M., Lowery, J., Alves, I., et al. (2005). Biousian glycopeptides penetrate the blood-brain barrier. Tetrahedron Asymmetry 16, 65-75. doi: 10.1016/j.tetasy.2004.11.038.
21. Egleton, R., and Davis, T. (2005). Development of neuropeptide drugs that cross the blood-brain barrier. Neurotherapeutics 2, 44-53. doi: 10.1602/neurorx.2.1.44.
22. Egleton, R. D., Mitchell, S. A., Huber, J. D., Janders, J., Stropova, D., Polt, R., et al. (2000). Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 881, 37-46. doi: 10.1016/S0006-8993(00)02794-3.
23. Egleton, R. D., Mitchell, S. A., Huber, J. D., Palian, M. M., Polt, R., and Davis, T. P. (2001). Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J. Pharmacol. Exp. Ther. 299, 967-972. doi: 10.1602/neurorx.2.1.44.
24. Elmagbari, N. O., Egleton, R. D., Palian, M. M., Lowery, J. J., Schmid, W. R., Davis, P., et al. (2004). Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J. Pharmacol. Exp. Ther. 311, 290-297. doi: 10.1124/jpet.104.069393.
25. Falconer, R. A., and Toth, I. (2007). Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. Bioorg. Med. Chem. 15, 7012-7020. doi: 10.1016/j.bmc.2007.07.048.
26. Fichna, J., Perlikowska, R., Gach, K., do-Rego, J. C., Cravezic, A., Janecka, A., et al. (2010). The novel endomorphin degradation blockers Tyr-Pro-DClPhe-Phe-NH2 (EMDB-1) and Tyr-Pro-Ala-NH2 (EMDB-2) prolong endomorphin-2 action in rat ileum in vitro. Chem. Biol. Drug Des. 76, 77-81. doi: 10.1111/j.1747-0285.2010.00977.x.
27. Gentilucci, L. (2004). New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem. 4, 19-38. doi: 10.2174/1568026043451663.
28. Griffin, B. D., and O'Driscoll, C. M. (2011). Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2, 1633-1653.
29. Hackler, L., Zadina, J. E., Ge, L. J., and Kastin, A. J. (1997). Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 18, 1635-1639. doi: 10.1016/S0196-9781(97)00259-3.
30. Horvat, S. (2001). Opioid peptides and their glycoconjugates: structure-activity relationships. Curr. Med. Chem. 1, 133-154. Available online at: http://dx.doi.org/10.2174/1568015013358581.
31. Hruby, V. J., al-Obeidi, F., and Kazmierski, W. (1990). Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem. J. 268, 249-262.
32. Hruby, V. J., and Balse, P. M. (2000). Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 7, 945-970. doi: 10.2174/0929867003374499.
33. Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., and Morris, H. R. (1975). Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258, 577-580. doi: 10.1038/258577a0.
34. Jinsmaa, Y., Marczak, E., Fujita, Y., Shiotani, K., Miyazaki, A., Li, T., et al. (2006). Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1. Pharmacol. Biochem. Behav. 84, 252-258. doi: 10.1016/j.pbb.2006.05.005.
35. Jordan, B. A., and Devi, L. A. (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700. doi: 10.1038/21441.
36. Kawai, M., Fukuta, N., Ito, N., Kagami, T., Butsugan, Y., Maruyama, M., et al. (1990). Preparation and opioid activities of N-methylated analogs of [D-Ala2,Leu5]enkephalin. Int. J. Pept. Protein Res. 35, 452-459. doi: 10.1111/j.1399-3011.1990.tb00072.x.
37. Koda, Y., Del Borgo, M., Wessling, S. T., Lazarus, L. H., Okada, Y., Toth, I., et al. (2008). Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg. Med. Chem. 16, 6286-6296. doi: 10.1016/j.bmc.2008.04.020.
38. Kokotos, G., Martin, V., Constantinou-Kokotou, V., and Gibbons, W. A. (1996). Synthesis of medicinally useful lipidicalpha-amino acids, 2-amino alcohols and diamines. Amino Acids 11, 329-343. doi: 10.1007/BF00807940.
39. Kream, R. M. (Inventor). (2003). Chimeric Hybrid Analgesics. Patent Number: WO2003090697 US.
40. Kream, R. M., Liu, N. L., Zhuang, M., Esposito, P. L., Esposito, T. R., Stefano, G. B., et al. (2007). Synthesis and pharmacological analysis of a morphine/substance P chimeric molecule with full analgesic potency in morphine-tolerant rats. Med. Sci. Monit. 13, BR25-BR31.
41. Levac, B. A., O'Dowd, B. F., and George, S. R. (2002). Oligomerization of opioid receptors: generation of novel signaling units. Curr. Opin. Pharmacol. 2, 76-81. doi: 10.1016/S1471-4892(02)00124-8.
42. Li, T. Y., Fujita, Y., Tsuda, Y., Miyazaki, A., Ambo, A., Sasaki, Y., et al. (2005). Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J. Med. Chem. 48, 586-592. doi: 10.1021/jm049384k.
43. Negri, L., Lattanzi, R., Tabacco, F., Orru, L., Severini, C., Scolaro, B., et al. (1999). Dermorphin and deltorphin glycosylated analogues:? synthesis and antinociceptive activity after systemic administration. J. Med. Chem. 42, 400-404. doi: 10.1021/jm9810699.
44. Palian, M. M., Boguslavsky, V. I., O'Brie, D. F., and Polt, R. (2003). Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. J. Am. Chem. Soc. 125, 5823-5831. doi: 10.1021/ja0268635.
45. Pignatello, R., Puleo, A., Guccione, S., Raciti, G., Acquaviva, R., Campisi, A., et al. (2005). Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. I. Synthesis and biological evaluation of lipophilic conjugates of tranylcypromine. Eur. J. Med. Chem. 40, 1074-1079. doi: 10.1016/j.ejmech.2005.05.009.
46. Poduslo, J. F., and Curran, G. L. (1994). Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain. Res. Mol. Brain Res. 23, 157-162. doi: 10.1016/0169-328X(94)90222-4.
47. Polt, D. R., Dhanasekaran, M., Egleton, R. D., Bilsky, E. J., Yamamura, H. I., Porreca, F., et al. (2005a). Endorphins: biousian glycopeptides cross the BBB due to surfactant properties. Abstr. Pap. Am. Chem. Soc. 229, U116.
48. Polt, R., Dhanasekaran, M., and Keyari, C. M. (2005b). Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med. Res. Rev. 25, 557-585. doi: 10.1002/med.20039.
49. Polt, R. (2008). "Biomedicine of enkephalin-derived glycopeptide analgesics," in Glycoscience eds B. Fraser-Reid, K. Tatsuta, J. Thiem (Berlin; Heidelberg: Springer), 2525-2543. doi: 10.1007/978-3-540-30429-6_65.
50. Polt, R., Porreca, F., Szabo, L. Z., Bilsky, E. J., Davis, P., Abbruscato, T. J., et al. (1994). Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 91, 7114-7118. doi: 10.1073/pnas.91.15.7114.
51. Przewlocki, R., and Przewlocka, B. (2001). Opioids in chronic pain. Eur. J. Pharmacol. 429, 79-91. doi: 10.1016/S0014-2999(01)01308-5.
52. Sakurada, C., Sakurada, S., Hayashi, T., Katsuyama, S., Tan-No, K., and Sakurada, T. (2003). Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem. Pharmacol. 66, 653-661. doi: 10.1016/S0006-2952(03)00391-5.
53. Schiller, P. W., and DiMaio, J. (1982). Opiate receptor subclasses differ in their conformational requirements. Nature 297, 74-76. doi: 10.1038/297074a0.
54. Silvius, J. R. (2002). Lipidated peptides as tools for understanding the membrane interactions of lipid-modified proteins. Curr. Top. Membr. 52, 371-95. doi: 10.1016/S1063-5823(02)52015-9.
55. Smetanova, L., Stetinova, V., Svoboda, Z., and Kvetina, J. (2011). Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver. Acta Medica (Hradec Kralove) 54, 3-8.
56. Stewart, J. M., Getto, C. J., Neldner, K., Reeve, E. B., Krivoy, W. A., and Zimmermann, E. (1976). Substance P and analgesia. Nature 262, 784-785. doi: 10.1038/262784a0.
57. Toth, I. (1994). A novel chemical approach to drug delivery: lipidic amino acid conjugates. J. Drug Target. 2, 217-239. doi: 10.3109/10611869408996805.
58. Vaccarino, A. L., and Kastin, A. J. (2000). Endogenous opiates: 1999. Peptides 21, 1975-2034. doi: 10.1016/S0196-9781(00)00345-4.
59. Vaccarino, A. L., Olson, G. A., Olson, R. D., and Kastin, A. J. (1999). Endogenous opiates: 1998. Peptides 20, 1527-1574. doi: 10.1016/S0196-9781(99)00166-7.
60. Varamini, P., Goh, W. H., Mansfeld, F. M., Blanchfield, J. T., Wyse, B. D., Smith, M. T., et al. (2013). Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation. Bioorg. Med. Chem. 21, 1898-1904. doi: 10.1016/j.bmc.2013.01.044.
61. Varamini, P., Hussein, W. M., Mansfeld, F. M., and Toth, I. (2012a). Synthesis, biological activity and structure-activity relationship of endomorphin-1/substance P derivatives. Bioorg. Med. Chem. 20, 6335-6343. doi: 10.1016/j.bmc.2012.09.003.
62. Varamini, P., Mansfeld, F. M., Blanchfield, J. T., Wyse, B. D., Smith, M. T., and Toth, I. (2012b). Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS ONE 7:e41909. doi: 10.1371/journal.pone.0041909.
63. Varamini, P., Mansfeld, F. M., Blanchfield, J. T., Wyse, B. D., Smith, M. T., and Toth, I. (2012c). Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J. Med. Chem. 55, 5859-5867. doi: 10.1021/jm300418d.
64. Wang, J., Hogenkamp, D. J., Tran, M., Li, W. Y., Yoshimura, R. F., Johnstone, T. B. C., et al. (2006). Reversible lipidization for the oral delivery of leu-enkephalin. J. Drug. Target. 14, 127-136. doi: 10.1080/10611860600648221.
65. 5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263, 1308-1316.
66. 5]-enkephalin (DPDPE). J. Pharmacol. Exp. Ther. 298, 848-856.
67. Wood, I. S., and Trayhurn, P. (2003). Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. The British journal of nutrition 89, 3-9. doi: 10.1079/BJN2002763.
68. Zadina, J. E., Hackler, L., Ge, L.-J., and Kastin, A. J. (1997). A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386, 499-502. doi: 10.1038/386499a0.